Literature DB >> 2328194

Effect of intermittent administration of omeprazole on serum pepsinogens in duodenal ulcer patients and healthy volunteers.

I Biemond1, L F Crobach, J B Jansen, C B Lamers.   

Abstract

1. Omeprazole, a substituted benzimidazole inhibitor of the gastric H+/K(+)-APT-ase, was administered orally at a dose of 20 mg in the morning of 3 consecutive days, followed by a period of 4 days without medication, and this intermittent dosage regimen was continued for 4 weeks. 2. During intermittent administration of omeprazole to 10 patients with duodenal ulcer disease and 10 healthy volunteers concentrations of serum pepsinogen A and serum pepsinogen C were monitored by sensitive and specific radioimmunoassays to study whether the effect of this treatment on serum pepsinogens is different between patients and normal subjects and to evaluate whether serum pepsinogen levels can be used to assess compliance with therapy. 3. Administration of omeprazole for 3 days induced significant increases in pepsinogen A and pepsinogen C serum concentrations, which rapidly fell after stopping the omeprazole intake. The pattern of serum pepsinogens after stopping the drug was different for duodenal ulcer patients and normal subjects. Both pepsinogens were intra-individually related in both patients and healthy subjects when compared during the first and last 3-day course with omeprazole, but in duodenal ulcer patients both pepsinogens tended to be higher in the last treatment course, while the opposite was found in the normal subjects. 4. The present study confirms that serum pepsinogen concentrations are higher in duodenal ulcer patients than in normal subjects, but also shows for the first time that serum pepsinogens in the patients respond differently upon stimulation with omeprazole.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2328194      PMCID: PMC1380117          DOI: 10.1111/j.1365-2125.1990.tb03665.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  20 in total

1.  Effect of single and repeated intravenous doses of omeprazole on pentagastrin stimulated gastric acid secretion and pharmacokinetics in man.

Authors:  J B Jansen; P Lundborg; L C Baak; J Greve; M Ohman; C Stöver; K Röhss; C B Lamers
Journal:  Gut       Date:  1988-01       Impact factor: 23.059

2.  Effect of single and repeated doses of oral omeprazole on gastric acid and pepsin secretion and fasting serum gastrin and serum pepsinogen I levels.

Authors:  H P Festen; H A Tuynman; J Défize; G Pals; R R Frants; J P Straub; S G Meuwissen
Journal:  Dig Dis Sci       Date:  1986-06       Impact factor: 3.199

3.  Relationships among serum pepsinogen I, serum pepsinogen II, and gastric mucosal histology. A study in relatives of patients with pernicious anemia.

Authors:  I M Samloff; K Varis; T Ihamaki; M Siurala; J I Rotter
Journal:  Gastroenterology       Date:  1982-07       Impact factor: 22.682

4.  Effect of oral omeprazole on serum gastrin and serum pepsinogen I levels.

Authors:  H P Festen; J C Thijs; C B Lamers; J M Jansen; G Pals; R R Frants; J Défize; S G Meuwissen
Journal:  Gastroenterology       Date:  1984-11       Impact factor: 22.682

5.  Pachydermoperiostosis, hypertrophic gastropathy, and peptic ulcer.

Authors:  S K Lam; W K Hui; J Ho; K P Wong; J I Rotter; I M Samloff
Journal:  Gastroenterology       Date:  1983-04       Impact factor: 22.682

6.  Omeprazole in Zollinger-Ellison syndrome. Effects of a single dose and of long-term treatment in patients resistant to histamine H2-receptor antagonists.

Authors:  C B Lambers; T Lind; S Moberg; J B Jansen; L Olbe
Journal:  N Engl J Med       Date:  1984-03-22       Impact factor: 91.245

7.  Double-blind multicentre comparison of omeprazole and ranitidine in the treatment of reflux oesophagitis.

Authors:  E C Klinkenberg-Knol; J M Jansen; H P Festen; S G Meuwissen; C B Lamers
Journal:  Lancet       Date:  1987-02-14       Impact factor: 79.321

8.  Elevated serum pepsinogen I and II levels differ as risk factors for duodenal ulcer and gastric ulcer.

Authors:  I M Samloff; G N Stemmermann; L K Heilbrun; A Nomura
Journal:  Gastroenterology       Date:  1986-03       Impact factor: 22.682

9.  Effect of omeprazole--a gastric proton pump inhibitor--on pentagastrin stimulated acid secretion in man.

Authors:  T Lind; C Cederberg; G Ekenved; U Haglund; L Olbe
Journal:  Gut       Date:  1983-04       Impact factor: 23.059

10.  The ratio of pepsinogen A to pepsinogen C: a sensitive test for atrophic gastritis.

Authors:  K Borch; C K Axelsson; H Halgreen; M D Damkjaer Nielsen; T Ledin; P B Szesci
Journal:  Scand J Gastroenterol       Date:  1989-09       Impact factor: 2.423

View more
  3 in total

1.  Serum pepsinogens after interruption of long-term maintenance therapy with omeprazole in patients with reflux esophagitis.

Authors:  I Biemond; E C Klinkenberg-Knol; C B Lamers; S G Meuwissen
Journal:  Dig Dis Sci       Date:  1993-05       Impact factor: 3.199

2.  Diagnostic value of serum pepsinogen C in patients with raised serum concentrations of pepsinogen A.

Authors:  I Biemond; J Kreuning; J B Jansen; C B Lamers
Journal:  Gut       Date:  1993-10       Impact factor: 23.059

3.  Analysis of long-term serological and histological changes after eradication of Helicobacter pylori.

Authors:  Kensuke Fukuda; Masaaki Kodama; Kazuhiro Mizukami; Kazuhisa Okamoto; Ryo Ogawa; Yuka Hirashita; Masahide Fukuda; Kazumi Togo; Osamu Matsunari; Tadayoshi Okimoto; Kazunari Murakami
Journal:  J Clin Biochem Nutr       Date:  2022-03-31       Impact factor: 3.179

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.